GlassScriptPhysician profile
Joshua Webb
NPI 1063405017
$2,843.64
in general payments reported to CMS, 2019-2025
35 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $580 · 2023: $693 · 2024: $662 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $514.11 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $427.01 | 2021-2025 | |
| Abbott Laboratories | $269.35 | 2022-2024 | Eterna, Freestyle Libre 3 |
| Pfizer INC. | $147.36 | 2021-2025 | |
| Exact Sciences Corporation | $131.22 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $125.29 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.50 | 2021-2022 | |
| Lilly USA, LLC | $113.89 | 2021-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $83.69 | 2022-2025 | Wegovy, Saxenda |
| Bausch Health US, LLC | $76.87 | 2021 | |
| Gilead Sciences, INC. | $71.86 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $68.06 | 2023-2025 | M-M-R II, Gardasil 9, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $60.82 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $58.71 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $54.57 | 2023-2024 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.98 | 2021-2025 | Shingrix, Bexsero, Rotarix |
| Sanofi Pasteur INC. | $49.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.45 | 2021-2022 | |
| Amgen INC. | $38.72 | 2021-2022 | |
| Hologic Sales and Service, LLC | $31.97 | 2025 | Aptima |
| Kowa Pharmaceuticals America, INC. | $31.06 | 2025 | Zoryve |
| Dexcom, INC. | $29.73 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $29.02 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $23.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.01 | 2021 | |
| Acadia Pharmaceuticals INC | $22.76 | 2024 | Daybue |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.92 | 2024 | Xifaxan |
| Corcept Therapeutics | $19.27 | 2022 | |
| Amarin Pharma, INC. | $17.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 | |
| Esperion Therapeutics, INC. | $16.11 | 2024 | Nexletol |
| Echosens North America, INC. | $15.27 | 2024 | Fibroscan |
| Otsuka America Pharmaceutical, INC. | $15.19 | 2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $14.07 | 2024 | Horizant |
| Mylan Specialty L.P. | $13.13 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.